Organisation: MGI Pharma

MGI Pharma, Inc., a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products for oncology and acute care applications. The company markets Aloxi (palonosetron hydrochloride) Injection, Dacogen (decitabine) for Injection, and Gliadel Wafer (polifeprosan 20 with carmustine implant) in the United States. The Company directly markets its products in the U.S. and collaborates with partners to reach international markets. The company was formerly known as Molecular Genetics, Inc. and changed its name to MGI Pharma, Inc. in January, 1990. The company was founded in 1979 and is headquartered in Bloomington, Minnesota. It has facilities in Bloomington, Minnesota; Lexington, Massachusetts; and Baltimore, Maryland. As of January 25, 2008, MGI Pharma, Inc. operates as a subsidiary of Eisai Corporation of North America, Inc.